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Summary
Background Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with 
advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected 
melanoma at high risk of recurrence. We report results from the preplanned interim analysis.
Methods We did a multicentre, open-label, randomised controlled phase 3 trial at 48 centres in the UK between 
July 18, 2007, and March 29, 2012. Patients aged 16 years or older with American Joint Committee on Cancer stage 
(AJCC) stage IIB, IIC, and III cutaneous melanoma were randomly allocated (1:1), via a central, computer-based 
minimisation procedure, to receive intravenous bevacizumab 7·5 mg/kg, every 3 weeks for 1 year, or to observation. 
Randomisation was stratifi ed by Breslow thickness of the primary tumour, N stage according to AJCC staging criteria, 
ulceration of the primary tumour, and patient sex. The primary endpoint was overall survival; secondary endpoints 
included disease-free interval, distant-metastases interval and quality of life. Analysis was by intention-to-treat. This 
trial is registered as an International Standardised Randomised Controlled Trial, number ISRCTN81261306.
Findings 1343 patients were randomised to either the bevacizumab group (n=671) or the observation group (n=672). 
Median follow-up was 25 months (IQR 16–37) in the bevacizumab group and 25 months (17–37) in the observation 
group. At the time of interim analysis, 286 (21%) of 1343 enrolled patients had died: 140 (21%) of 671 patients in the 
bevacizumab group, and 146 (22%) of 672 patients in the observation group. 134 (96%) of patients in the bevacizumab 
group died because of melanoma versus 139 (95%) in the observation group. We noted no signifi cant diﬀ erence in 
overall survival between treatment groups (hazard ratio [HR] 0·97, 95% CI 0·78–1·22; p=0·76); this fi nding persisted 
after adjustment for stratifi cation variables (HR 1·03; 95% CI 0·81–1·29; p=0·83). Median duration of treatment with 
bevacizumab was 51 weeks (IQR 21–52) and dose intensity was 86% (41–96), showing good tolerability. 180 grade 3 or 4 
adverse events were recorded in 101 (15%) of 671 patients in the bevacizumab group, and 36 (5%) of 672 patients in 
the observation group. Bevacizumab resulted in a higher incidence of grade 3 hypertension than did observation 
(41 [6%] vs one [<1%]). There was an improvement in disease-free interval for patients in the bevacizumab group 
compared with those in the observation group (HR 0·83, 95% CI 0·70–0·98, p=0·03), but no signifi cant diﬀ erence 
between groups for distant-metastasis-free interval (HR 0·88, 95% CI 0·73–1·06, p=0·18). No signifi cant diﬀ erences 
were noted between treatment groups in the standardised area under the curve for any of the quality-of-life scales over 
36 months. Three adverse drug reactions were regarded as both serious and unexpected: one patient had optic neuritis 
after the fi rst bevacizumab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a 
haemopericardium after receiving two bevacizumab infusions and was later identifi ed to have had signifi cant 
predisposing cardiovascular risk factors.
Interpretation Bevacizumab has promising tolerability. Longer follow-up is needed to identify an eﬀ ect on the primary 
endpoint of overall survival at 5 years.
Funding Cancer Research UK.
Copyright © Corrie et al. Open Access article distributed under the terms of CC BY.
Introduction
Melanoma is a chemoresistant cancer. Fewer than 50% of 
patients with resected locoregional melanoma survive to 
5 years.1 Adjuvant trials assessing interferon alfa have 
shown that the drug delays melanoma recurrence, but has 
only a small overall survival benefi t.2 The low survival 
benefi t and high treatment-related toxic eﬀ ects associated 
with interferon alfa mean that no internationally agreed 
standard adjuvant treatment is available for patients with 
high-risk melanoma.
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Targeting the proangiogenic VEGF with the 
monoclonal antibody bevacizumab provides modest 
survival gains for patients with some types of advanced 
cancer.3 Proangiogenic factors play a key part in 
neovascularisation of invading and metastasising cancer; 
therefore, VEGF blockade after locoregional surgery 
might prevent spread of disease.4,5 VEGF concentration 
measured in either the tissue or serum of patients with 
melanoma correlate with disease stage and tumour 
burden, and might be prognostic.6–10 Findings from 
clinical trials of small-molecule inhibitors with selectivity 
for VEGFR in patients with advanced melanoma have 
been disappointing;11–13 however, bevacizumab activity 
was more promising.14,15 We therefore did this study of 
adjuvant bevacizumab versus observation after resection 
of melanoma to establish whether angiogenesis 
inhibition would oﬀ er clinical benefi t in patients at high 
risk of recurrence.
Methods
Study design and patients
We did this open-label, randomised controlled phase 3 
trial between July 18, 2007, and March 29, 2012, at 
48 centres in the UK (appendix). Eligible patients were at 
least 16 years old, with histological confi rmation of 
completely resected American Joint Committee on 
Cancer stage IIB (T3bN0M0 and T4aN0M0), IIC 
(T4bN0M0), or III (TxN1–3M0) cutaneous melanoma. 
Sentinel lymph-node biopsy was recommended but not 
mandatory; complete lymphadenectomy was done if the 
sentinel node was positive. Inclusion criteria were an 
Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–1; a life expectancy of 6 months 
or more; and adequate haematological, liver, and renal 
function. Exclusion criteria were evidence of distant or 
non-regional lymph-node metastases (established by CT 
or MRI scanning of the body and head within 8 weeks of 
randomisation), incomplete resection of melanoma, or 
adjuvant radiotherapy that was ongoing at randomisation. 
Treatment assignment could not take place within 4 
weeks of surgery or in the presence of unhealed wounds, 
but had to be within 12 weeks of a patient’s latest surgery 
for melanoma. Previous chemotherapy, immunotherapy, 
or hormonal therapy for melanoma was not allowed 
within 12 weeks of randomisation. Patients had to be free 
from drug administration for 28 days either side of any 
procedure. Patients were also excluded if they had 
uncontrolled hypertension, or a history or evidence of 
any disorder that might increase risk of bleeding. 
All patients gave written informed consent. We 
obtained regulatory approval, and ethics approval from a 
multicentre research ethics committee. Because this 
interim analysis was preplanned, and in view of the 
absence of an international standard adjuvant therapy for 
melanoma, the independent data monitoring committee 
supported publication of these results in advance of the 
fi nal analysis anticipated in 2017.
Randomisation and masking
Eligible patients were randomly assigned centrally in a 1:1 
ratio using a computer-based minimisation algo rithm, to 
receive either adjuvant bevacizumab or standard obser-
vation. Randomisation was stratifi ed by Breslow thickness 
of the primary tumour, N stage according to AJCC staging 
criteria,1 ulceration of the primary tumour (absent, 
present, or unknown), and patient sex. This was an open-
labelled trial and therefore participants, investigators, and 
trial staﬀ  were not masked to group allocation.
Procedures
For patients randomly assigned to bevacizumab, 
7·5 mg/kg was given via 30 min intravenous infusion 
once every 3 weeks for 1 calendar year (maximum 
17 infusions), or until disease recurred. No dose 
reductions were permitted, but patients could have a 
maximum of two drug holidays (at their request), each of 
no more than 6 weeks. If a patient required any further 
dose interruptions, treatment was discontinued.
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Figure 1: Trial profi le
HR=hazard ratio. *Patients were included in the longitudinal quality-of-life analysis if they had completed at least 
two questionnaires.
671 assigned to bevacizumab 672 assigned to observation
19 did not receive intervention
 10 because of patient choice
 1 local recurrence
 4 wound healing complications or surgical 
  intervention
 1 case of cellulitis
 1 case of thrombus
 1 case of hypertension
 1 diagnosis of central retinal vein occlusion
652 received intervention
291 discontinued early
 119 because of recurrence
 112 because of unacceptable toxic eﬀects 
 28 because of patient choice
 1 patient died
 10 cases of unacceptable dose interruption 
   due to surgical intervention or investigation
 7 wound healing complications
 12 unplanned discontinuations
 2 had a new second malignancy
671 included in primary analysis
592 analysed for health-related quality of life*
672 included in primary analysis
623 analysed for health-related quality of life* 
3394 participants assessed for eligibility
2051 excluded 
 1357 did not meet inclusion criteria
 694 declined to participate
1343 randomised
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Patients in both arms were assessed every 3 months 
for 2 years; then every 6 months for 3 years; and 
annually thereafter until 10 years from randomisation, 
death, or withdrawal for any other reason. Research 
nurses contacted patients at 6 month intervals between 
annual clinic visits to enable survival information to be 
updated. Medical history, physical examination, full 
blood count, clotting, clinical chemistry, and protein 
urinalysis were assessed at baseline and every study 
visit. Chest radiography was done at 3 and 6 months 
after randomisation; then every 6 months up to 3 years, 
thereafter annually up to 5 years. Patients completed 
the European Organisation for Research and Treatment 
of Cancer Quality-of-Life Questionnaire (EORTC 
QLQ-C30, version 3.0) every 3 months for 2 years, then 
at 2·5, 3, 4, and 5 years. Adverse events reported during 
the fi rst year by patients in the observation group and 
for 28 days after the last bevacizumab infusion for 
those in the bevacizumab group were recorded 
according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), 
version 3.0. Locoregional and distant recurrence were 
managed as per local hospital practice. Treatment upon 
disease progression was determined by local 
investigator decision for both patient groups. Treatment 
options included surgery; systemic therapy; 
radiotherapy, dependent on type of recurrence; and 
patient choice.
We ascertained BRAF mutation status in archived 
tumour tissue with a cobas4800 (Roche Diagnostics, 
West Sussex, UK) test or by pyrosequencing. NRAS 
mutation status was identifi ed in BRAF wild-type 
tumours by pyrosequencing. NRAS status was not 
established for BRAF mutant tumours, because NRAS 
and BRAF mutations are generally mutually exclusive.
Outcomes
The primary endpoint of the trial was overall survival, 
which we defi ned as the time from date of randomisation 
until date of death from any cause, or censored at the last 
known date alive. Secondary endpoints were disease-free 
interval, distant-metastasis-free interval, safety and toxic 
eﬀ ects, and health-related quality of life. Tertiary 
endpoints were assessment of biological predictive and 
prognostic markers. Disease-free interval was defi ned as 
the time from the date of randomisation until the date of 
fi rst tumour recurrence (including distant and 
locoregional recurrence), or date of death due to 
melanoma. Distant-metastasis-free interval was defi ned 
as the time from the date of randomisation until the date 
of fi rst distant recurrent disease, or date of death due to 
melanoma.
Statistical analysis
Patients who withdrew consent for further follow-up 
were included in the analysis, but censored at the time of 
withdrawal. The expected rates of 1 year and 5 year overall 
survival in the standard observation group were roughly 
85% and 40%, respectively. A sample size of 1320 patients 
(660 patients per group) was needed to detect an absolute 
increase in 5 year overall survival from 40% to 48%, with 
85% power and a 5% signifi cance level, which equates to 
a hazard ratio (HR) of 0·80. An interim analysis was 
planned after all patients had fi nished the treatment and 
Bevacizumab 
(n=671)
Observation 
(n=672)
Sex
Male 377 (56%) 376 (56%)
Female 294 (44%) 296 (44%)
Median age (years) 56 (18–87) 55 (19–88)
Median BMI (kg/m²) 27·7 (15·8–68·6) 27·5 (15·7–50·2)
Breslow thickness of primary tumour (mm)
<2·0 199 (30%) 200 (30%)
>2–4 203 (30%) 204 (30%)
>4 221 (33%) 216 (32%)
Unknown 48 (7%) 52 (8%)
Ulceration of primary tumour
Yes 258 (39%) 257 (38%)
No 311 (46%) 321 (48%)
Unknown 102 (15%) 94 (14%)
N classifi cation
N0+Nx 187 (28%) 181 (27%)
N1a+N2a 142 (21%) 139 (21%)
Other N classes 342 (51%) 352 (52%)
ECOG performance status
0 602 (90%) 592 (88%)
1 67 (10%) 80 (12%)
Unknown 2 (<1%) 0
AJCC stage*
IIB 103 (15%) 109 (16%)
IIC 84 (13%) 72 (11%)
IIIA 104 (15%) 95 (14%)
IIIB 242 (36%) 253 (38%)
IIIC 138 (21%) 143 (21%)
Sentinel lymph-node biopsy done
Yes 218 (32%) 222 (33%)
No 450 (67%) 446 (66%)
Unknown 3 (1%) 4 (1%)
BRAF status established 299 (45%) 346 (51%)
Wild type 173/299 (58%) 181/346 (52%)
V600 mutant 126/299 (42%) 165/346 (48%)
NRAS status established in only 
patients with BRAF wild-type
120 (69%) 119 (66%)
Wild type 67/120 (56%) 66/119 (55%)
Q61 mutant 53/120 (44%) 53/119 (45%)
Data are n (%) median (range), or n/N (%), unless otherwise indicated. 
BMI=body-mass index. ECOG=Eastern Cooperative Oncology Group. 
AJCC=American Joint Committee on Cancer Stage. *82 (22%) of the 368 patients 
with stage IIB and IIC tumours had sentinel lymph-node biopsy, and were 
therefore pathologically lymph-node negative.
Table 1: Baseline characteristics
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been in the study for at least 1 year, the results of which 
are reported here.
Survival curves were constructed with the Kaplan-
Meier method and compared with a log-rank χ² test. A 
Cox proportional hazard model was used to obtain HRs 
and associated 95% CIs. HRs were calculated for 
prognostic subgroups and a HR plot constructed.16 
Multivariable Cox-regression models were used to adjust 
the treatment eﬀ ect for stratifi cation variables, to assess 
the independent predictors of overall survival and 
disease-free interval, and to assess treatment interaction 
with the tumour mutation status and whether 
hypertension, fi tted as a time-dependent covariate, 
aﬀ ected disease-free interval. We did a sensitivity analysis 
excluding ineligible patients.
We scored quality-of-life data on a scale from 0 to 100 
according to the algorithm described in the EORTC 
QLQ-C30 scoring manual.17 High scores imply an 
improvement in function or quality of life, but more 
severe symptoms. Quality-of-life data were analysed by 
standardised area-under-the-curve analysis18 and 
compared across trial groups with Wilcoxon rank-sum 
tests.
Reported p values are two-sided. All analyses were 
done by intention to treat with the SAS statistical package 
(version 9.3). This trial is registered as an International 
Standardised Randomised Controlled Trial, number 
ISRCTN 81261306.
Role of the funding source
The sponsor and funder of the study had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. AM had full access to all the data 
in the study and the corresponding author had fi nal 
responsibility for the decision to submit for publication.
Results
1343 patients were randomly assigned to either the 
bevacizumab group (n=671) or the observation group 
(n=672; fi gure 1). Patients’ baseline characteristics were 
similar between groups (table 1). 975 (73%) patients had 
resected AJCC stage III melanoma, 515 (38%) patients 
had an ulcerated primary tumour, and 440 (32%) patients 
underwent sentinel lymph-node biopsy. 368 (27%) 
patients had no known nodal involvement (N0 and Nx), 
281 (21%) had microscopic lymph-node involvement 
(N1a and N2a), and 694 (52%) had macroscopic lymph-
node involvement. We subsequently identifi ed 11 (1%) of 
enrolled patients  as ineligible; three in the bevacizumab 
group and eight in the observation group: fi ve had 
metastatic disease, fi ve had incomplete surgery, and one 
had stage IIA melanoma. These patients were included 
in all analyses on an intention-to-treat-basis. 44 (3%) 
of 1343 enrolled patients were lost to follow-up or 
withdrew consent during the study. Six patients withdrew 
consent for further follow-up (fi ve [1%] in the 
bevacizumab group and one [<1%]  in the observation 
group) and 38 patients were lost to follow-up (23 [3%] vs 
15 [2%]).
19 (3%) of the 671 patients in the bevacizumab group 
did not start treatment and 291 (43%) discontinued 
treatment early (fi gure 1). The median time from surgery 
to start of bevacizumab was 11 weeks (IQR 4–14). The 
median number of infusions of bevacizumab was 16 
(IQR 7–17) and median duration of treatment was 
51 weeks (IQR 21–52). Median dose intensity for the 
652 patients who started treatment was 86% (IQR 41–96). 
361 (54%) patients completed the planned treatment 
(either all 17 infusions or 1 year of treatment; fi gure 1). 
The main reasons for patients failing to complete the full 
course of bevacizumab were recurrence or toxic eﬀ ects. 
Severity was graded as 3 or 4 in 34 (30%) of the 112 cases 
of unacceptable toxic eﬀ ects. The most common toxic 
Figure 2: Overall survival (A) and distant metastasis-free interval (B), analysis unadajusted for stratifi cation 
factors
HR=hazard ratio.
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eﬀ ect causing treatment discontinuation was hyper-
tension in 36 (5%) patients. Only 261 (3%) of 8126 
bevacizumab infusions were delayed for more than 
7 days. The main reasons for delay were for planned drug 
holidays or toxic eﬀ ects (data not shown).
286 (21%) of 1343 enrolled patients had died at the time 
of the interim analysis (140 [21%] of 671 patients in the 
bevacizumab group and 146 [22%] of 672 patients in the 
observation group). 134 (96%) of patients in the 
bevacizumab group died because of melanoma versus 
139 (95%) in the observation group. The median follow-
upbwas 25 months (IQR 17–37). Median overall survival 
had not yet been reached. We noted no signifi cant 
diﬀ erence in overall survival between treatment groups 
(fi gure 2); this fi nding persisted after adjustment for 
stratifi cation variables (HR 1·03; 95% CI 0·81–1·29; 
p=0·83). Overall survival at 1 year was 95% (95% CI 
93–97) for patients in the bevacizumab group and 94% 
(92–96) for those in the observation group. Multivariable 
analysis identifi ed disease stage, ECOG performance 
status, and primary melanoma ulceration as independent 
predictors of overall survival (table 2). The treatment 
eﬀ ect remained non-signifi cant for overall survival after 
adjustment for the three prognostic variables (HR 1·02, 
95% 0·81–1·28; p=0·89).
We recorded an improvement in disease-free interval 
for patients in the bevacizumab group compared with 
those in the observation group (fi gure 3). At 1 year, 77% 
(95% CI 73–80) of patients given bevacizumab were 
disease free, as were 70% (66–73) for those who 
underwent observation. The treatment eﬀ ect for disease-
free interval remained irrespective of the stratifi cation 
variables (fi gure 4). Multivariable analysis identifi ed 
disease stage, Breslow thickness of the primary 
melanoma, trial group, and ECOG performance status as 
independent predictors of disease-free interval (table 2). 
There was a suggestion of an improved distant-
metastasis-free interval with bevacizumab, but it was not 
signifi cant (fi gure 2). Types of recurrence and the 
treatment methods used for recurrence were similar 
between treatment groups (table 3). 184 (65%) of the 
283 local recurrences and 68 (16%) of the 430 distant 
recurrences were treated with surgery alone. Results 
from the analysis of disease-free interval were unchanged 
in a sensitivity analysis excluding the ineligible patients.
BRAF status was available for 645 (48%) patients 
(table 1). A BRAF V600 mutation was detected in 
291 (45%) of the 645 assessed patients (table 1). Suﬃ  cient 
material remained to undertake NRAS testing in 
239 (68%) of 354 patients with BRAF wild-type; 106 (44%) 
of these patients had a mutation at codon 61. No 
codon 12 or 13 mutations were detected. The interaction 
between treatment and BRAF status was not signifi cant 
(p=0·10); however, in patients with BRAF mutant 
tumours, we noted an improvement in the disease-free 
interval in those given bevacizumab (fi gure 3). Disease-
free interval did not diﬀ er signifi cantly between treatment 
groups in the wild-type BRAF population (fi gure 3).
180 grade 3 or 4 adverse events were recorded in 
101 (15%) of 671 patients in the bevacizumab group and 
36 (5%) of 672 patients in the observation group. 
216 (32%) patients had hypertension in the bevacizumab 
group (table 4), but the disorder was generally 
manageable; we recorded grade 3 or 4 hypertension in 
41 (6%) patients (table 4). Hypertension did not 
signifi cantly aﬀ ect disease-free interval (HR 0·85, 95% CI 
0·67–1·09; p=0·20) after adjustment for trial group.
Three adverse drug reactions were regarded as both 
serious and unexpected. One patient developed optic 
neuritis after the fi rst bevacizumab infusion, which 
resulted in 90% loss of vision in one eye. A second 
patient had persistent erectile dysfunction, but continued 
to receive treatment. A third patient died of a 
haemopericardium after receiving two bevacizumab 
infusions, and was later identifi ed to have had signifi cant 
predisposing cardiovascular risk factors.
8846 (87%) of 10 151 quality-of-life forms were returned. 
1215 (90%) of 1343 patients returned at least two forms 
n (%; N=1343) Number of 
events (%)
Hazard ratio 
(95% CI)
p value
Overall survival
Disease stage <0·0001
II 368 (27%) 45 (12%) 1·00 ··
III (N1a and N2a) 281 (21%) 39 (14%) 1·42 (0·91–2·21) ··
III (other N) 694 (52%) 202 (29%) 3·05 (2·16–4·32) ··
ECOG performance status <0·0001
0 1194 (89%) 235 (20%) 0·54 (0·39–0·73) ··
1 147 (11%) 50 (34%) 1·00 ··
Ulceration 0·02
Yes 515 (38%) 109 (21%) 1·00 ··
No 632 (47%) 121 (19%) 0·68 (0·52–0·89) ··
Unknown 196 (15%) 56 (29%) 0·75 (0·53–1·06) ··
Disease-free interval
Disease stage <0·0001
II 368 (27%) 118 (32%) 1·00 ··
III (N1a and N2a) 281 (21%) 76 (27%) 1·12 (0·82–1·52) ··
III (other N) 694 (52%) 370 (53%) 2·78 (2·20–3·51) ··
Breslow thickness (mm) <0·0001
≤2·0 399 (30%) 160 (40%) 1·00 ··
>2–4 407 (30%) 165 (41%) 1·25 (1·01–1·57) ··
>4 437 (33%) 200 (46%) 1·74 (1·38–2·20) ··
Unknown 100 (7%) 39 (39%) 0·84 (0·59–1·19) ··
Trial group 0·03
Treatment 671 (50%) 264 (39%) 0·83 (0·70–0·98) ··
Observation 672 (50%) 300 (45%) 1·00 ··
ECOG performance status 0·04
0 1194 (89%) 490 (41%) 1·30 (1·02–1·67) ··
1 147 (11%) 73 (50%) 1·00 ··
ECOG=Eastern Cooperative Oncology Group.
Table 2: Results from the multivariate analyses for overall survival and disease-free interval
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and were included in the analyses: 592 (88%) of 
671 patients in the bevacizumab group and 623 (93%) of 
672 patients in the observation group. Baseline quality-
of-life scores were similar in both groups (data not 
shown). After Bonferroni adjustment for multiple 
testing, no signifi cant diﬀ erences were noted between 
treatment groups in the standardised area under the 
curve for any of the quality-of-life scales over 36 months 
(table 5).
Discussion
Our fi ndings show an improvement in disease-free 
interval with bevacizumab in patients with resected 
melanoma at high risk of recurrence as compared with 
observation alone. Median disease-free interval and 
overall survival have not yet been reached. The curves for 
disease-free interval remain separate at this interim 
analysis. Follow-up of patients and timing of clinic visits 
were similar between treatment groups. Clearly, it will be 
important to ascertain whether this treatment eﬀ ect 
ultimately translates into a benefi t in overall survival at 
fi nal analysis, which is follow-up driven and planned for 
when all patients have been on study for a minimum of 
5 years, at which time 736 events are anticipated. The 
conditional power for futility of the primary outcome of 
overall survival at this interim analysis was 35%.
To our knowledge, AVAST-M is one of the largest 
adjuvant melanoma trials and the largest bevacizumab 
monotherapy study ever undertaken (panel). By contrast 
with most published adjuvant melanoma trials, we chose 
overall survival as the primary endpoint in AVAST-M. 
Patients and regulatory agencies increasingly value 
relapse-free survival as a primary endpoint in this setting, 
which is justifi ed now that systemic therapies have been 
shown to improve overall survival in advanced disease.19–21 
However, when we started AVAST-M bevacizumab was a 
new drug with signifi cant toxic eﬀ ects (albeit reported 
mainly in combination with cytotoxic chemotherapy), 
and so we felt that a benefi t in overall survival would 
need to be shown to change clinical practice. We chose 
disease-free interval and distant-metastasis-free interval 
as secondary endpoints to identify the eﬀ ect of 
bevacizumab on disease recurrence. However, disease-
free interval in this trial could be indiciative of relapse-
free survival, because only seven additional deaths from 
other causes without recurrence would have been 
included in an analysis of relapse-free survival; these 
inclusions would not have changed the results from 
those reported for disease-free interval.
The most frequently used adjuvant melanoma 
treatment worldwide is interferon alfa. The role of 
adjuvant interferon is controversial and, despite being 
used in both the USA and Europe, it is not an 
international standard of care. Moreover, in many 
countries adjuvant therapy for resected melanoma is not 
routinely oﬀ ered at all. The controversy regarding use of 
interferon surrounds the interpretation of its clinical 
Figure 3: Disease-free interval for all patients (A), for patients with a BRAF mutation (B), and for those with 
BRAF wild type (C)
HR=hazard ratio.
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signifi cance attributable to marginal survival benefi ts 
alongside potential for harm due to drug side-eﬀ ects. 
Trials assessing diﬀ erent doses and formulations of 
interferon alfa have not identifi ed the optimum adjuvant 
regimen for patients with melanoma,2 while this 
treatment is recognised to be associated with substantial 
toxic eﬀ ects, including liver dysfunction, fatigue, and 
depression.22,23 Other immunotherapeutic strategies, 
including several vaccines, have been rigorously tested in 
patients with melanoma, with disappointing results 
overall.24 This outcome is exemplifi ed by the results of 
the DERMA randomised trial, in which a MAGE A3 
vaccine did not improve relapse-free survival (its fi rst co-
primary endpoint) in patients with resected stage III 
melanoma expressing the MAGE A3 antigen.25 Our 
results suggest that the extent of patient benefi t oﬀ ered 
with bevacizumab might be similar to that with 
interferon alfa for the endpoint of relapse-free survival 
(HR for interferon alfa 0·82, 95% CI 0·77–0·87), but the 
overall survival benefi t (0·89, 0·82–0·96) on ifterferon 
alfa was not noted with bevacizumab.2
At this interim analysis, few patients had received 
immunotherapy or targeted therapy at relapse, and the 
most common intervention was surgery. This fi nding is 
consistent with the high rate of locoregional recurrence 
as a result of the fairly low use of sentinel node biopsy 
and the inclusion of high risk primary tumours, together 
with the scarcity of active systemic therapy options 
Figure 4: Hazard ratio plot of the treatment eﬀ ect by prognostic factors for disease-free interval
O–E=observed–expected events. HR=hazard ratio.
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available until more recently. The eﬀ ect of subsequent 
treatments at relapse on overall survival is likely to be 
small at this time point, but will be of greater importance 
in the future. Even so, the delay in melanoma recurrence 
noted with adjuvant bevacizumab in this trial might be 
clinically relevant.
Bevacizumab monotherapy seems to be well tolerated: 
grade 3 or 4 adverse events associated with bevacizumab 
were fewer than those reported with interferon, 
depending on the dose used, although cross-trial 
comparisons should be made with caution.22,23
There was no obvious safety signal associated with 
surgical interventions or haemorrhage to account for 
patients’ early discontinuation. The protocol specifi ed 
dose interruptions around surgical interventions, 
requiring 28 days free from drug administration either 
side of any procedure, and preventing drug admini-
stration in the presence of any unhealed wound. Drug-
associated complications in wound healing seem to be 
negligible, and only a few patients failed to complete 
planned treatment due to unacceptable delays in wound 
healing, suggesting that, in routine clinical practice, 
withholding treatment in such circumstances need not 
be so stringent. Fairly high patient withdrawal rates have 
been reported in both low-dose and high-dose adjuvant 
interferon alpha trials: 15% in the UK AIM HIGH trial23 
and 37% in the EORTC 18991 trial.22 However, it is worth 
noting that, in the EORTC 18991 trial, grade 3 and 4 
adverse events were reported in 12% of patients receiving 
placebo. Withdrawal rates will be aﬀ ected by the duration 
of intended treatment, but low-level chronic side-eﬀ ects 
in an otherwise fi t population might account for patients 
electing to stop prematurely and this should be 
considered in future adjuvant trial designs. A placebo-
controlled trial might have improved patient willingness 
to remain on treatment for longer, but the additional cost 
of a placebo would have been prohibitive in this charity-
funded trial.
Multivariate analyses of disease-free interval and overall 
survival were undertaken to explore whether some 
subsets of patients were more likely to benefi t from 
therapy than others. Disease stage and Breslow thickness 
were the most signifi cant predictors of disease-free 
interval; disease stage and ECOG performance status 
were the most signifi cant predictors of overall survival. A 
tenth of patients had an ECOG performance status score 
of 1 on trial entry; the reason for their poor outcome is not 
apparent, but will be assessed fully in the fi nal analysis.
AVAST-M includes a prespecifi ed translational study, 
aimed at identifying predictive and prognostic 
biomarkers. We retrospectively obtained tumour blocks 
with which to test BRAF mutation status; therefore, the 
possibility of ascertainment bias cannot be excluded. The 
45% BRAF V600 mutation rate within the assessed 
population is consistent with data derived from other 
advanced melanoma populations. Firm conclusions 
about whether bevacizumab might result in a longer 
disease-free interval for the subgroup of patients with 
BRAF mutant tumours cannot yet be made, but further 
analysis including multivariate analyses  will be 
undertaken at the fi nal analysis. The subgroup of patients 
assessed for NRAS mutation was too small to provide 
reliable results for disease-free interval and overall 
survival at this stage. Firm conclusions from the BRAF 
subgroup analysis cannot yet be made, but we will do 
multivariate analyses at the fi nal analysis. Investigation 
into the biological basis for this initially unexpected 
fi nding is ongoing, but it is consistent with emerging 
evidence of the MAP kinase pathway playing a role in the 
control of VEGF expression. Studies in a mouse model of 
Bevacizumab (n=671) Observation (n=672)
Any disease recurrence reported
No 408/671 (61%) 374/672 (56%)
Yes* 263/671 (39%) 298/672 (44%)
Locoregional recurrence fi rst 125/263 (48%) 150/298 (50%)
Distant recurrence fi rst 138/263 (52%) 148/298 (50%)
Locoregional recurrence
N (%) 130 (19%) 153 (23%)
Type†
Local recurrence at primary site 61 (47%) 64 (42%)
In-transit metastases 44 (34%) 44 (29%)
Regional lymph-node metastases‡ 55 (42%) 71 (46%)
Treatment†
None 3 (2%) 7 (5%)
Chemotherapy 7 (6%) 9 (6%)
Immunotherapy or biological therapy 3 (3%) 5 (3%)
Radiotherapy 28 (22%) 23 (15%)
Surgery 110 (85%) 131 (86%)
Other 4 (3%) 5 (3%)
Unknown 2 (2%) 1 (1%)
First distant recurrence
N (%) 207 (31%) 223 (33%)
Type
M1a (skin, subcutaneous, or lymph nodes with 
normal LDH)
27 (13%) 28 (12%)
M1b (lung) 47 (23%) 55 (25%)
M1c (other sites or raised LDH) 133 (64%) 140 (63%)
Treatment†
None 43 (21%) 33 (15%)
Chemotherapy 70 (34%) 74 (33%)
Immunotherapy or biological therapy 28 (14%) 23 (10%)
Radiotherapy 50 (24%) 47 (21%)
Surgery 49 (24%) 64 (29%)
Other 12 (6%) 28 (13%)
Unknown 9 (4%) 6 (3%)
Data are n/N (%) or n (%), unless otherwise indicated. *An additional three patients (one in the bevacizumab group 
and two in the observation group) who died of melanoma before details of their recurrence being reported are 
included in the analyses of disease-free interval. †Patients can have more than one site of locoregional recurrence and 
treatment for recurrence recorded. ‡20 (16%) of the patients with regional lymph-node recurrence had previously had 
a sentinel lymph-node biopsy.
Table 3: Patterns of disease recurrence
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melanoma and human melanoma tissue have shown 
that BRAF signalling aﬀ ects VEGF production.26 In 
BRAF mutant mouse xenografts, BRAF inhibition 
resulted in increased T-cell infi ltration of tumours, an 
eﬀ ect that was mediated by downregulation of VEGF. If 
this mechanism applies to melanomas in human beings, 
it would provide a basis for the selection of patients for 
bevacizumab therapy, and a rationale for future potential 
combination regimens.
Three trials testing adjuvant bevacizumab in 
combination with chemotherapy have been reported in 
patients with colon27,28 and breast cancer.29 All three trials 
had disease-free survival as the primary endpoint, and 
none identifi ed any improvement. These negative trials 
have called into question whether inhibition of 
micrometastatic disease by bevacizumab is a realistic 
goal. Angiogenesis inhibitors have immunomodulatory 
eﬀ ects30,31 and (by contrast with epithelial cancers), 
melanoma is a highly immunogenic tumour. It is 
possible that any benefi t attributable to bevacizumab is 
due to immunological eﬀ ects, which can persist beyond 
the treatment period. Both immunological and angio-
genic biomarkers are now being explored with tumour 
and blood samples collected from most patients recruited 
to the AVAST-M trial.
Bevacizumab Observation p value*
Function
Physical functioning 96·1 (86·7–100) 96·7 (88·3–100) 0·16
Role functioning 94·4 (79·2–100) 94·8 (79·2–100) 0·50
Emotional functioning 89·0 (75·9–97·9) 87·5 (74·0–97·2) 0·23
Cognitive functioning 93·8 (81·3–100) 95·8 (83·3–100) 0·009
Social functioning 94·4 (79·2–100) 95·8 (83·3–100) 0·06
Symptom
Fatigue 13·3 (4·4–26·2) 11·1 (3·2–22·9) 0·02
Nausea and vomiting 0 (0–2·8) 0 (0–2·8) 0·51
Pain 8·3 (0–20·0) 7·5 (0–22·2) 0·68
Dyspnoea 0 (0–9·5) 0 (0–8·3) 0·94
Insomnia 12·5 (0–28·2) 12·5 (0–33·3) 0·75
Appetite loss 0 (0–4·2) 0 (0–5·6) 0·38
Constipation 0 (0–6·7) 0 (0–4·2) 0·04
Diarrhoea 0 (0–5·6) 0 (0–5·6) 0·29
Financial diﬃ  culties 0 (0–8·3) 0 (0–4·8) 0·06
Global health
Quality of life 81·3 (68·1–89·6) 81·9 (68·8–91·1) 0·26
Data are median (IQR), unless otherwise indicated. Scores are on a scale of 0–100, with high values for function scale 
and low values for symptom scales representing improved quality of life. *Unadjusted. p values less than 0·003 would 
be signifi cant after adjustment with Bonferroni correction for multiple testing.
Table 5: Quality of life standardised area-under-curve analyse
Bevacizumab (n=671) Observation (n=672)
1–2 3 4 1–2 3–4 4
Auditory 10 (1%) 1 (<1%) 0 5 (1%) 0 0
Blood or bone marrow 34 (5%) 2 (<1%) 0 24 (4%) 1 (<1%) 0
Hypertension 175 (26%) 41 (6%) 0 40 (6%) 1 (<1%) 0
Other cardiac 19 (3%) 3 (<1%) 2 (1%) 4 (1%) 2 (<1%) 0
Dermatological 188 (28%) 3 (<1%) 0 83 (12%) 5 (1%) 0
Endocrine 24 (4%) 0 0 8 (1%) 1 (<1%) 0
Fatigue 222 (33%) 3 (<1%) 1 (<1%) 58 (9%) 1 (<1%) 0
Other constitutional symptoms 78 (12%) 0 0 32 (5%) 0 0
Diarrhoea 84 (13%) 0 0 22 (3%) 2 (<1%) 0
Other gastrointestinal 249 (37%) 3 (<1%) 0 62 (9%) 3 (<1%) 1 (<1%)
Haemorrhage or bleeding 152 (23%) 1 (<1%) 0 12 (2%) 1 (<1%) 0
Infection 190 (28%) 7 (1%) 0 83 (12%) 5 (1%) 0
Lymphatic 42 (6%) 1 (<1%) 0 45 (7%) 0 0
Metabolic 75 (11%) 12 (2%) 0 31 (5%) 1 (<1%) 0
Musculoskeletal 91 (14%) 1 (<1%) 0 26 (4%) 3 (<1%) 1 (<1%) 
Neurological 89 (13%) 7 (1%) 2 (<1%) 58 (9%) 1 (<1%) 0
Ocular 29 (4%) 1 (<1%) 1 (<1%) 5 (1%) 1 (<1%) 0
Headache 150 (22%) 5 (1%) 0 23 (3%) 2 (<1%) 0
Other pain 249 (37%) 12 (2%) 0 140 (21%) 8 (1%) 0
Pulmonary 135 (20%) 1 (<1%) 0 45 (7%) 1 (<1%) 0
Altered menstruation 23 (3%) 3 (<1%) 0 5 (1%) 1 (<1%) 0
Thromboembolic event 1 (<1%) 1 (<1%) 0 0 0 0
Second malignancy 0 2 (<1%) 0 4 (1%) 
Data are n (%). Adverse events are recorded for all patients who had an event of grade 3 or 4 severity and include any other adverse events that were recorded in 10% or more patients. Patients can have more than 
one type of adverse event. We classifi ed events are classifi ed with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). 
Table 4: Overview of adverse events
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Eﬀ ective treatment to prevent melanoma relapse 
remains an unmet need. Bevacizumab is not yet 
established as an eﬀ ective treatment for melanoma and 
other drugs are being tested in the adjuvant setting. The 
results of these trials, alongside the fi nal results of the 
AVAST-M trial, will have a key role in identifying future 
adjuvant strategies for this disease.
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